Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,261 across all filing types
Latest filing 2024-07-16 Environmental & Social …
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Updates
Environmental & Social Information Classification · 95% confidence The document is titled 'Business Responsibility and Sustainability Report' for the financial year 2023-24 and is explicitly stated to be part of the Annual Report for the same year. It contains detailed disclosures on sustainability strategy, environmental protection, ethics, and social responsibility, including data on employees, CSR, grievance mechanisms, and business activities. The document is comprehensive and exceeds 5,000 characters, indicating it is the full report rather than a brief announcement. The content aligns with Environmental & Social Information (ESG) reporting rather than financial statements or governance changes. Therefore, the document fits the category of Environmental & Social Information (SR).
2024-07-16 English
Shareholders meeting
AGM Information Classification · 100% confidence The document is a Notice of the 45th Annual General Meeting (AGM) of AstraZeneca Pharma India Limited scheduled for August 8, 2024. It includes details about the meeting agenda such as adoption of financial statements for the year ended March 31, 2024, dividend declaration, director re-appointment, and cost auditor remuneration. The document references the Annual Report for the financial year 2023-24 being available on the company's website but does not contain the full report itself. The document is a formal notice sent to shareholders in compliance with SEBI and MCA regulations, describing the AGM logistics and voting procedures. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, including the Notice of Meeting. The document length (15,000 characters) and content confirm it is not a brief announcement or a certification but a full AGM Notice document.
2024-07-16 English
We are enclosing herewith the Certificate dated June 3, 2024 issued the RTA of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, issued by the Registrar and Transfer Agent confirming compliance with dematerialization and related securities regulations for the period 01.06.2024 to 30.06.2024. It is addressed to stock exchanges and the company secretary, and it confirms regulatory compliance rather than presenting financial data or company performance. The document length is short (3280 characters) and it is a compliance certificate rather than a financial report or announcement of a meeting or vote. It fits best under Regulatory Filings (RNS) as it is a regulatory compliance certificate and does not contain financial statements, management discussion, or other report types.
2024-07-12 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, issued by the Registrar and Transfer Agent confirming compliance with dematerialization and related securities regulations for the period 01.06.2024 to 30.06.2024. It is addressed to stock exchanges and is a compliance certificate rather than a financial report or announcement of financial results. The document length is short (3280 characters) and it primarily serves as a regulatory compliance certificate. It does not contain financial statements, management discussion, or other report content. Therefore, it fits best under Regulatory Filings (RNS) as a compliance document.
2024-07-12 English
Please find the enclosed document of the Company as per the captioned subject for your reference.
Notice of Dividend Amount Classification · 95% confidence The document is a communication addressed to stock exchanges and shareholders regarding the tax deduction at source (TDS) on dividends for the financial year 2023-24. It references the Board of Directors' recommendation of a final dividend, details the applicable tax provisions for resident and non-resident shareholders, and provides instructions for submitting relevant tax forms and documents. The document does not contain financial statements, earnings data, or detailed financial analysis. It is primarily an announcement related to dividend taxation and shareholder communication rather than a financial report or regulatory filing. The document length is about 10,948 characters, which is substantial but the content is focused on dividend tax communication. This fits best under the category of Notice of Dividend Amount (DIV), as it relates to dividend payment and associated tax information for shareholders.
2024-07-08 English
Updates
Notice of Dividend Amount Classification · 95% confidence The document is a communication addressed to stock exchanges and shareholders regarding the tax deduction at source (TDS) on dividends for the financial year 2023-24. It references the Board of Directors' recommendation of a final dividend, details the applicable tax provisions for resident and non-resident shareholders, and provides instructions for submitting relevant forms and documents. The document does not contain financial statements, earnings data, or detailed financial analysis. It is primarily an announcement related to dividend tax withholding procedures and shareholder communication. It is not a full Annual Report, Earnings Release, or any other detailed financial report. The document is a formal communication to shareholders and regulators about dividend-related tax matters, which fits best under the category of Notice of Dividend Amount (DIV), as it relates to dividend payment and associated tax information.
2024-07-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.